Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rowatanal is a topical cream indicated for the symptomatic relief of pain, itching, and discomfort associated with internal and external hemorrhoids (piles), anal pruritus, and perianal irritation. Developed by Rowa Pharmaceuticals and marketed in the Philippines by New Marketlink Pharmaceutical Corporation, the formulation typically combines astringent and protective agents such as bismuth subgallate and zinc oxide with the soothing properties of menthol. Bismuth subgallate and zinc oxide act as mild antiseptics and astringents that form a protective layer over the affected mucosa, helping to reduce inflammation and protect the area from further irritation. Menthol provides a cooling sensation and relieves itching by activating TRPM8 receptors. The product is applied topically to the affected area or rectally using an applicator nozzle for internal treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rowatanal.